MORBIDITY AND MORTALITY DATA OF HYPERTROPHIC CARDIOMYOPATHY IN HUNGARY

Hypertrophic cardiomyopathy is a primary disorder of the myocardium with reasonable morbidity and mortality. Morbidity and mortality data on the disease are not fully explored in Hungary. One-hundred-and-seventy-four patients with hypertrophic cardiomyopathy (99 males, 75 females, average age: 53?17 years) from the Szeged HCM Registry were evaluated. Maximal left ventricular thickness, determined by transthoracic echocardiography, was 23?6 mm; in 33 patients a left ventricular outflow tract gradient >30 mmHg was present (average resting peak gradient 55?31 mmHg). Apart of medical treatment, in 10 patients ICD implantation, in 8 patients percutaneous transluminal septal myocardium ablation (PTSMA), in 4 patients percutaneous coronary intervention (PCI), in 4 patients myectomy, in one patient ACBG and mitral valve replacement, and in 3 patients pacemaker implantation was performed. In the whole patient cohort 13 patients developed documented atrial fibrillation (11 males, avearge age 55?13 years), 3 patients developed stroke and 4 patients developed systolic heart failure. Follow up data was available on 138 patients (79%). During follow up 12 patients have died (8.7%, 8 males, 4 females, average age: 59?19 years). Survival time from diagnosis to death was 151?104 month (range 37-351 month). The cause of death was sudden cardiac death in 6 patients (50%, 5 males, average age 58?14 years), therapy refractory heart failure in 2 patients (17%, 1 male, average age 40?32 years), stroke in 2 patients (17%, 1 male, average age 56?5 years), and it was not cardiac death in 2 patients (1 gastric cancer, 1 pneumonia). In one more case heart transplantation was performed due to progressive systolic heart failure.